| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725217 | Clinical Gastroenterology and Hepatology | 2018 | 10 Pages |
Abstract
In 3 Phase 3 studies, 8 weeks' treatment with glecaprevir/pibrentasivr produced an SVR12 in at least 93% of patients with chronic HCV genotype 2, 4, 5, or 6 infection without cirrhosis, with virologic failure in less than 1%. The drug combination had a safety profile comparable to 12 week's treatment with glecaprevir/pibrentasvir. ClinicalTrials.gov numbers: NCT02640482 (ENDURANCE-2), NCT02636595 (ENDURANCE-4), and NCT02243293 (SURVEYOR-II).
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Tarik Asselah, Kris V. Kowdley, Neddie Zadeikis, Stanley Wang, Tarek Hassanein, Yves Horsmans, Massimo Colombo, Filipe Calinas, Humberto Aguilar, Victor de Ledinghen, Parvez S. Mantry, Christophe Hezode, Rui Tato Marinho, Kosh Agarwal, Frederik Nevens,